List of programme's course units, number of exams (i.e. how many times the exam was taken in a year) and average marks
The data refer to last year. A course unit may include modules, subgroups, integrated exams. Proficiency tests are not included in the list.
| Course unit | Number of times exam was taken | Average mark |
|---|---|---|
| ANALYTICAL CHALLENGES IN THE BIOPHARMACEUTICAL FIELD | 1 | 30 |
| ADVANCED IMMUNOLOGY | 19 | 29 |
| APPLIED GENOMICS | 1 | 29 |
| INDUSTRIAL PROCESSES FOR RECOMBINANT DRUGS | 26 | 27 |
| BIOMOLECULAR SIMULATIONS FOR DRUG DESIGN | 21 | 28 |
| SAFETY PHARMACOLOGY AND TOXICOLOGY OF BIOPHARMACEUTICALS | 4 | 28 |
| EUROPEAN AND INTERNATIONAL REGULATION AND PATENTS | 2 | 30 |
| BIOSENSORS | 9 | 29 |
| ANTIVIRAL AND ANTIMICROBIAL STRATEGIES | 24 | 28 |
| MOLECULAR INTERACTION NETWORKS (I.C.) | 19 | 28 |
| NANOFORMULATION OF BIOLOGICALS | 1 | 30 |
| STEM CELLS AND 3D ORGANOID SYSTEMS | 28 | 30 |
| NANOBIOTECHNOLOGY (I.C.) | 21 | 27 |
| MOLECULAR INTERACTION NETWORKS (I.C.) | 2 | 29 |
| NEUROBIOTECHNOLOGY | 15 | 30 |
| STRUCTURAL BASES OF MOLECULAR INTERACTIONS | 3 | 24 |
| INDUSTRIAL SCALE UP OF BIOPROCESSES | 1 | 27 |
| LEGAL AND ECONOMIC ASPECTS OF PHARMACEUTICAL BIOTECHNOLOGY (I.C.) | 22 | 29 |
| MOLECULAR MECHANISMS OF DISEASES | 5 | 26 |
| MOLECULAR SIGNALLING TRANSDUCTION | 1 | 28 |
| SAFETY AND QUALITY OF BIOPHARMACEUTICAL PRODUCTS (I.C.) | 24 | 29 |
| GENOMICS OF DISEASES (I.C.) | 29 | 28 |
| ADVANCED TECHNIQUES FOR THE STUDY OF METABOLISM IN VIVO | 13 | 29 |
| INDUSTRIAL BIOTECHNOLOGICAL APPLICATIONS (I.C.) | 21 | 28 |
| BIOSENSORS | 30 | 29 |
| PHARMACOTHERAPY OF BIOLOGICAL DRUGS | 23 | 29 |